查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
膀胱癌市场:KOL的洞察
市场调查报告书
商品编码
1796157

膀胱癌市场:KOL的洞察

KOL Insight - Bladder Cancer
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告深入分析了膀胱癌标靶治疗的不断发展，重点关注已上市和后期研发产品。基于对北美和欧洲关键意见领袖的访谈，报告探讨了目前的治疗标准、检查点抑制剂和抗体药物偶联物的临床影响，以及基因治疗和新型免疫调节剂等新兴疗法的潜力。深入了解专家对治疗选择的看法、患者特征的影响、正在进行和即将进行的临床试验的重要性，以及新数据和技术创新推动的治疗途径预期转变。报告还探讨了患者分层方面的挑战、生物标记驱动方法的采用以及膀胱保留策略在临床实践中的未来作用。

关键问题解答

  • 1.目前建议的膀胱癌治疗方法有哪些？为什么？
  • 2.专家如何评估已核准的检查点抑制剂在膀胱癌中的作用和影响？
  • 3.Padoseb（enformab vedotin）+ Keytruda（pembrolizumab）组合的临床意义为何？
  • 4.皮下注射製剂如何影响膀胱癌治疗？
  • 5.预计膀胱癌治疗模式将如何随着患者人口统计和治疗线的变化而变化？
  • 6.哪些病患特征对尿路上皮癌的治疗方案影响最大？
  • 7.哪些正在进行的临床试验可能会影响未来的处方趋势？
  • 8.研发产品必须达到哪些疗效和安全性基准才能与目前的市场领导者竞争？

部分参与专家名单

  • 英国伦敦巴兹癌症中心泌尿生殖肿瘤学主任及教授
  • 荷兰阿姆斯特丹大学医学中心泌尿外科副教授
  • 法国巴黎索邦大学泌尿科教授（APHP）
  • 美国德州达拉斯德州大学西南医院系统泌尿外科诊所医学主任
  • 美国佛罗里达州坦帕市南佛罗里达大学莫尔萨尼医学院肿瘤内科教授
  • 加拿大安大略省多伦多市多伦多大学医学院副教授、加拿大泌尿肿瘤学会主席

研究方法

"治疗趋势" 报告透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，探讨关键疾病的当前和未来治疗前景。领域。关键意见领袖 (KOL) 的甄选是基于严格的标准，包括全球认可度、临床专业知识以及在治疗领域的影响力。每次访谈都配有精心设计的讨论指南。这些指南由我们与关键意见领袖合作开发，并由行业专家进行同行评审，确保问题全面且与当前市场动态相关。每份报告发布后，我们会持续 12 个月的市场监测，及时提供关键意见领袖对重要新闻事件、市场变化和市场发展的更新。

我们的报告有何独特之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供详细且可操作的见解。我们深厚的行业知识使我们能够提供相关且有价值的见解，帮助我们的客户掌握新兴趋势并有效解决复杂挑战。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解，我们的报告可提供您所需的准确性和可靠性。独家专访和数据，以及持续的市场监测，确保您全面了解市场动态。我们的报告涵盖 40 多个活跃疾病领域，包含 KOL 洞察和定量医生调查等医生情报，以及行业专家对医疗事务、数位健康、销售与行销、市场准入及其他领域问题的看法，助您做出更明智的数据驱动决策，在快速变化的行业中保持竞争力。

简介目录

This report provides an in-depth analysis of the evolving landscape of targeted therapies in bladder cancer, with a focus on both marketed and late-stage pipeline products. Drawing on interviews with leading key opinion leaders from North America and Europe, the report examines current standards of care, the clinical impact of checkpoint inhibitors and antibody-drug conjugates, and the potential of emerging therapies such as gene therapies and novel immunomodulators. Gain insights into expert perspectives on treatment selection, the influence of patient characteristics, the significance of ongoing and upcoming clinical trials, and the anticipated shifts in treatment pathways driven by new data and innovation. The report also addresses challenges in patient stratification, the adoption of biomarker-driven approaches, and the future role of bladder-sparing strategies in clinical practice.

Key Questions Answered:

  • 1. What are the current preferred therapies for bladder cancer and why?
  • 2. How do experts assess the role and impact of approved checkpoint inhibitors in bladder cancer?
  • 3. What is the clinical significance of the Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) combination?
  • 4. How could subcutaneous formulations affect bladder cancer treatment?
  • 5. How is the bladder cancer treatment landscape expected to evolve across patient segments and lines of therapy?
  • 6. Which patient characteristics most influence treatment selection in urothelial carcinoma?
  • 7. Which ongoing clinical trials are likely to impact future prescribing trends?
  • 8. What efficacy and safety benchmarks must pipeline products meet to compete with current market leaders?

Partial List of Participating Experts:

  • Director and Professor of Genitourinary Oncology at Barts Cancer Center, London, UK
  • Associate Professor of Urology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Professor of Urology, Sorbonne University APHP, Paris, France
  • Medical Director of the Urology Clinic at UT Southwestern Hospital System, Dallas, Texas, USA
  • Professor of Oncology and Internal Medicine at University of South Florida Morsani College of Medicine, Tampa, Florida, USA
  • Associate Professor of Medicine at the University of Toronto, Chair of the Genitourinary Medical Oncologists of Canada, Toronto, Ontario, Canada

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.